AZZA3

Azzas 2154 S.A. (AZZA3)

Azzas 2154 is Latin America's largest fashion group, born in August 2024 from the merger of Arezzo&Co and Grupo Soma. It gathers more than 20 brands across four verticals — shoes and handbags (Arezzo, Schutz, Anacapri, Alexandre Birman, Vans), women's fashion (FARM Rio, Animale, NV, Maria Filó), men's fashion (Reserva, Oficina, Foxton) and basics (Hering) — with net revenue of R$ 11.8 billion in 2025, an omnichannel operation and a growing international footprint through FARM Rio.

Sector: Textiles & Apparel · Share price: R$ 14.63 (close on Aug 25, 2026) · Dividend yield (12m): 16.93% · 52-week range: R$ 14.40 – 35.93

Full analysis of AZZA3 (produced by this site with AI, Jul 30, 2026)

Rating: 5.5/10 · Verdict: UNDER REVIEW · Estimated fair price: R$ 24.00 (range R$ 14.00–34.00)

July 30, 2026 review — valuation rebuilt from scratch, without looking at the share price. The previous version of this analysis made an error that deserves to be stated plainly: on July 21 we estimated fair value at R$ 26.00 and, nine sessions later, with no new CVM filing whatsoever, we cut it to R$ 19.00. What changed was the screen, not the company. That is anchoring, not analysis. We rebuilt it starting from cash-generating capacity and the country's cost of capital — figures that do not move because the stock fell.

What Azzas is worth, ignoring price: the company posts R$ 11.8 bn in net revenue and delivered a pre-IFRS-16 EBITDA margin of 13.3% in Q1 2025, 13.0% in Q4 2025 and 10.4% in Q1 2026. Discounting free cash flow at a 17.3% WACC (derived from long-term rates + Brazil equity premium + a governance premium), intrinsic value ranges from R$ 15.07 (margin stuck at the weak Q1 2026 pace forever) to R$ 31.79 (15% margin, with Hering no longer bleeding), centered on R$ 24.36 at the 13% margin the company demonstrably delivers. Beneath all of it sits a balance-sheet floor: R$ 13.56/share of tangible book, already excluding intangibles and the deferred tax credit.

The harshest finding of this review is in the income statement, not the chart. In Q1 2026 Azzas reported recurring net income of R$ 63.9 million — but pre-tax income was negative R$ 3.7 million. The entire profit came from R$ 67.6 million of tax credits. Operationally the company lost money and reported a profit. That invalidates the 4.6x P/E everyone quotes and explains why the deferred tax credit on the balance sheet jumped from R$ 1.15 bn to R$ 1.74 bn. Rating 5.5/10, verdict UNDER REVIEW — not because of the share price, but because the margin underpinning half the value range has not yet shown up in results.

Overview

Azzas owns Arezzo, Schutz, FARM Rio, Animale, Reserva and Hering. Instead of asking "is the stock cheap or expensive today?", this analysis asks the right question: what is this business worth, regardless of what the exchange is paying for it?

The math, in plain terms: Azzas sells R$ 11.8 billion a year. After paying suppliers, staff, rent and taxes, it can generate between R$ 650 million and R$ 1.07 billion of free cash flow annually, depending on whether the operation runs badly or well. Because money is expensive in Brazil (rates at 14.25%), that cash is worth less today than it would be in a low-rate country. Running that math, the whole company is worth between R$ 15 and R$ 32 per share, with the most likely point at R$ 24.

And there is a floor. If you broke the company up and sold only the tangible pieces — inventory, cash, receivables, stores and equipment — you would get R$ 13.56 per share. Below that, a buyer gets the Arezzo, FARM, Reserva and Hering brands for free.

The warning nobody is giving: in the first quarter of 2026 Azzas announced R$ 63.9 million of profit, but before taxes it posted a loss. The entire profit came from a tax credit — money it only benefits from if it earns profits in the future. In other words: that "profit" is not cash that came in. And dividends in 2026 have been zero.

Investment thesis

After July's slide, the AZZA3 thesis changed nature. It is no longer "deep value with a corporate catalyst" — it is an option on the reorganization of a conglomerate that does not work as one, with no defined timeline and a high carrying cost.

What supports it: (i) the price already embeds a lot of bad news — 0.41x book, 4.6x recurring earnings, 3.0x EBITDA, and only 17% above tangible book excluding tax credits; (ii) there is a theoretical buyer for the most valuable piece — FARM Rio, valued between R$ 2.5 bn (Preserva Asset) and R$ 5.5 bn (JP Morgan), against a R$ 3.3 bn market cap for the whole group; (iii) the company generates cash and has termed out its debt (82.7% long-term, only R$ 561 mn maturing within 12 months), so there is no financial urgency; (iv) 12.8% of shares outstanding are sold short — fuel for a violent rally if the FARM sale materializes.

What weighs against: the operation is deteriorating faster than the price is falling relative to value. Gross revenue -4.4%, recurring EBITDA -23.2%, recurring net income -45.7% in a sector that is growing 4.2% in value — explicit share loss. Rates will stay high longer than assumed (three Fed governors voting for a hike, Copom on hold, Focus at 14.00% by year-end), consumer confidence is at its lowest since March, and October's election starts being priced from August. And there is no income to pay for the wait: zero dividends declared in 2026.

In one sentence: the discount is real, but the clock does not run in favor of those waiting for free. Against a 14.25% Selic, carrying AZZA3 costs ~1.1% per month in opportunity cost — and the return depends on a corporate event with no date.

Strengths

  • The price already embeds a bad scenario. 0.41x book value, 4.6x recurring earnings and 3.0x EBITDA. The stock trades just 17% above tangible book excluding deferred tax credits (R$ 13.56/share) — in practice, the market assigns close to zero value to Arezzo, FARM, Reserva and Hering combined.
  • FARM Rio may be worth more than the whole company (for some). JP Morgan values the brand at R$ 4.4-5.5 bn; Preserva Asset, applying global peer multiples (Capri Holdings), arrives at R$ 2.5-3.0 bn. Even the conservative estimate equals 76-92% of the group's market cap. Morgan Stanley was hired in June to evaluate alternatives.
  • FARM's international arm is genuinely growing. R$ 276.3 mn in Q1 2026, +21.1% in US dollars, with EMEA+APAC +64.8% and the US +13.6% (68% of international revenue). Over the trailing 12 months, R$ 1.3 billion outside Brazil — an avenue independent of the indebted Brazilian consumer.
  • A balance sheet with no urgency. Gross debt of R$ 3.24 bn with only 17.3% maturing within 12 months (R$ 561 mn), against R$ 1.06 bn of cash and R$ 894 mn of credit card receivables. Leverage at 1.40x. The company can wait for the cycle to turn — it is not a forced seller of anything.
  • Visible capital discipline. Capex -27% in Q1 2026, cash cycle 20 days shorter, inventory days -15, six loss-making brands zeroed out (revenue -99.2%) and fixed expenses essentially flat (-0.6%) in a quarter of falling revenue. CFO Eric Alencar is delivering on what depends on him.
  • 12.8% of shares sold short. Roughly 26.5 million shares on loan (about 20% of free float) at a low average fee of 0.29% p.a. That is structural selling pressure today — and fuel for a disproportionate rally if the FARM sale is confirmed. On June 22, the mere announcement of the Morgan Stanley mandate sent the stock up 10.5% in a single session.

Weaknesses

  • No dividend — the income thesis is over. No distribution has been declared in 2026. The last shareholder notice dates from December 2025. The 13-15% yield displayed on data sites refers to November/December 2025 payments and will simply drop out of the trailing 12-month window by year-end. Anyone who bought for income bought a number that no longer exists.
  • Share loss, not just a bad cycle. IEMI projects Brazilian fashion retail at R$ 63.34 bn for the autumn/winter 2026 season, +4.2% in value. Azzas gross revenue from continuing brands fell 4.4% in Q1 2026. The ~9 percentage point gap is not explained by macro — it is execution.
  • The engine sits on the wrong side of the feud. Fashion Women (FARM, Animale, NV), inherited from Jatahy's Grupo Soma, grew 18.7% in 2025 and is the only expanding unit. Shoes & Bags (Arezzo, Schutz), CEO Birman's home turf, fell 1.2% in 2025 and 6.9% in Q1 2026. The vertical carrying the result is run by the partner who went to court — and it is the one being evaluated for sale.
  • Hering still shrinking double digits. Gross revenue -18.5% in Q1 2026, with sell-out -17.8%, 47 franchises closed over 12 months and 8 stores transferred to franchisees. Part of the drop is deliberate (normalizing channel inventory from 8 to 5 months of coverage, cutting negative-margin sales), but the practical result is the same: R$ 114 million less revenue in the quarter.
  • Half the revenue depends on the shopkeeper, not the consumer. The sell-in channel (franchise + wholesale) fell 10.9% in Q1 2026 versus -1.5% for sell-out. When credit tightens, the shopkeeper stops buying before the consumer stops consuming — and Azzas feels it amplified, with a one-to-two quarter lag.
  • High rates are expensive on the balance sheet. Net financial expense of R$ 184.6 mn in the quarter (+17.1%), with interest on borrowings +19.9%. On R$ 3.24 bn of CDI-linked debt, each percentage point of Selic consumes ~R$ 32 mn per year — half a quarter of recurring profit.
  • Sell-side consensus is stale. The median of 13 analysts is R$ 34.81 and the lowest target on the street is R$ 28 (Citi and BofA, both after downgrades). With the stock at R$ 15.84, even the street's most pessimistic view implies +77%. That is not a sign of a bargain — it is a sign that models have not been revised since Q1 2026 and the break of the all-time low.

Risks

  • The FARM sale not happening — or happening cheap. This is now risk number one, because the price already embeds some probability of value unlock. The company was explicit: no decision, no binding proposal, no defined structure. If the process cools off, the stock loses its only catalyst with a possible date. And there is a worse risk: selling the brand growing 18.7% for R$ 2.5-3 bn (depressed peer multiples) would leave shareholders with cash and with the shrinking part of the portfolio — unlocking value and destroying value can happen in the same transaction.
  • Higher rates for longer than the price assumes. The Fed held rates on July 29 for the fifth consecutive meeting, with three governors (Hammack, Kashkari and Logan) voting for a HIKE and a tightening bias for September if inflation does not ease. In Brazil, Copom meets Aug 4-5 with the Selic at 14.25% and the Focus survey projecting only 14.00% by year-end — a pause through October's election. Discretionary consumption is the last to benefit when the cycle turns, and the cycle has barely begun to turn.
  • Q2 2026 confirming the trend (August 12). If revenue and margin keep falling, recurring net income of R$ 717 mn (trailing 12 months) heads toward R$ 450-500 mn. The "cheap" 4.6x P/E becomes 6.5-7x without the stock moving a cent, and the R$ 1.74 bn deferred tax credit on the balance sheet comes into question — because it is only worth something if there is future profit to offset. In that scenario, book equity shrinks alongside earnings.
  • The shareholder war reigniting. The CAM-B3 arbitration remains open and June's truce is weeks old. The most likely trigger now is the FARM negotiation itself: setting price, structure and the use of proceeds with two controlling shareholders who have already sued each other is exactly the kind of decision that reopens the dispute. A disorderly split in the middle of a turnaround would destroy value rather than unlock it.
  • A consumer out of breath and foreign competition. Consumer confidence (FGV/IBRE) fell to 88.3 in July, the lowest since March, with the deterioration concentrated in lower-income households — precisely Hering's customer. Default rates are heading above 8%. Add Bershka's arrival, Zara's lower-price strategy and pressure from Shein/Shopee on the basics segment.
  • Election year and Brazil risk premium. October's election starts being priced from mid-August. Domestic consumption stocks with high operating leverage are the first to suffer in risk-off episodes — and AZZA3 entered that window at its all-time low, with no dividend cushion.

Scenarios

Otimista: Full margin with Hering neutral and rates easing

Hering stops costing ~2 pp of margin, sell-in normalizes and the pre-IFRS margin reaches 15%: ~R$ 1.07 bn of FCFF. That is R$ 31.79 at today's cost of capital; R$ 39.04 if the Selic eases toward ~11% (Ke 18%). If FARM is sold between 8x and 10x EBITDA, add R$ 6.81 to R$ 10.93 per share on top — the multiple arbitrage between the private market and the conglomerate. Indicative price: R$ 34.00.

Base: Margin returns to the 13% the company has already delivered

The pre-IFRS-16 EBITDA margin returns to the 13.0% of 2025 (delivered in Q1 2025 and Q4 2025), generating ~R$ 885 mn of FCFF per year. Discounted at a 17.3% WACC, equity is worth R$ 5.03 bn, or R$ 24.36/share. This requires neither a Hering turnaround nor corporate peace — only that the company stops deteriorating and returns to its own average. Indicative price: R$ 24.00.

Pessimista: Margin stuck at the Q1 2026 pace, no FARM sale

The pre-IFRS-16 EBITDA margin settles around 10.5% (the Q1 2026 pace) and the cost of capital does not ease. Free cash flow falls to ~R$ 650 mn/year and intrinsic value sits between R$ 11.96 (with fiscal stress) and R$ 15.07 (today's cost of capital). The balance-sheet floor — R$ 13.56/share of tangible book — becomes the dominant reference, and the risk shifts to goodwill impairment and a write-down of the R$ 1.74 bn deferred tax credit. Indicative price: R$ 14.00.

Valuation

Why we rebuilt it. On July 21 we published fair value of R$ 26.00 (range R$ 16-34). On July 30, with no new company filing, we cut it to R$ 19.00 (range R$ 12-28). The only thing that had changed was the quote. That is the classic anchoring error: the analysis becomes a mirror of the market and stops informing. We rebuilt it from scratch, ignoring the screen price.

Step 1 — how much cash the business generates. Normalized net revenue of R$ 11.8 bn (2025: R$ 11.83 bn; trailing 12 months to Mar/26: R$ 11.60 bn). We use the pre-IFRS-16 EBITDA margin — which already deducts store rent and is the honest economic figure for retail. The company delivered 13.3% in Q1 2025, 13.0% in Q4 2025 and 10.4% in Q1 2026. Hence the three levels: depressed 10.5% (the weak pace becomes permanent), normal 13.0% (the proven average) and full 15.0% (Hering stops costing ~2 pp of margin). We deduct normalized capex of R$ 320 mn/year, 20% tax on EBIT and R$ 100 mn of working capital.

Step 2 — what money costs. This is what almost every analysis gets wrong by copying peer multiples. Cost of equity comes from long-term rates (~13.5% nominal, consistent with inflation-linked bonds at CPI+7.2% and a flat DI curve at 14.2%) + 5.5% Brazil equity premium + 3.0% Azzas-specific premium (controlling shareholders in arbitration, guidance withdrawn, synergies never proven) = 20% cost of equity. With debt at CDI+1% (12.2% after tax) at 35% of capital, WACC lands at 17.3%. With 5% perpetual growth (4.5% inflation + 0.5% real), the fair multiple that FALLS OUT of this is 4.3x to 4.9x pre-IFRS EV/EBITDA — not because "the sector trades there", but because that is what the cash flow is worth at this cost of capital.

Step 3 — the matrix. Two variables drive value, and both are observable without looking at the quote: the margin the company delivers and the country's interest rate. Crossing them (value per share):

Cost of capital10.5% margin
depressed		13.0% margin
normal		15.0% margin
full
Selic ~11% (Ke 18%)R$ 19.45R$ 30.33R$ 39.04
Selic 14.25% (today)R$ 15.07R$ 24.36R$ 31.79
Fiscal stress (Ke 22%)R$ 11.96R$ 20.12R$ 26.66

Step 4 — the balance-sheet floor. None of these numbers depends on earnings: book value is R$ 38.77/share, but R$ 3.46 bn is intangible (brands and merger goodwill) and R$ 1.74 bn is deferred tax credit — which only becomes money if there is future profit. Stripping both leaves R$ 13.56/share of inventory, receivables, fixed assets and cash. Note the convergence: that floor nearly touches the worst corner of the matrix (R$ 11.96). Two independent methods pointing at the same bottom is the most reliable signal in this analysis.

Step 5 — FARM comes on top. A FARM Rio sale is not "good news that lifts the stock": it is a measurable multiple arbitrage. Inside the conglomerate, every real of EBITDA is worth 4.7x by our math. In the private market, a global fashion brand growing 21% in dollars is worth 8-10x. On an estimated R$ 425 mn of FARM EBITDA, the gap unlocks between R$ 6.81 and R$ 10.93 per share — ADDED to any range above, if and when the deal happens. That is the economic reason selling makes sense, even while handing over the fastest-growing brand.

A warning about reported earnings. Do not use the 4.6x P/E circulating out there. In Q1 2026 pre-tax income was negative R$ 3.7 mn and the R$ 63.9 mn of recurring profit came entirely from R$ 67.6 mn of tax credits. The same happened on a smaller scale in 2025: R$ 770.7 mn of recurring profit on roughly R$ 569 mn of pre-tax income. Azzas's reported profit exceeds its operating result because the company barely pays tax (ICMS subsidies + credit utilization). That is why we normalize tax at 20% in the model rather than accepting the income statement figure.

  • Discounted cash flow — normal margin (13.0%): R$ 24.36 — Primary method. Net revenue of R$ 11.8 bn × 13.0% pre-IFRS-16 EBITDA margin (proven average: 13.3% in Q1 2025 and 13.0% in Q4 2025) = R$ 1,534 mn. Less R$ 320 mn capex, 20% tax on R$ 1,144 mn of EBIT and R$ 100 mn of working capital = R$ 885 mn of FCFF. Discounted at a 17.3% WACC with 5% growth = R$ 7,197 mn EV, less R$ 2,167 mn net debt = R$ 5,030 mn equity ÷ 206.5 mn shares.
  • DCF — depressed margin (10.5%) made permanent: R$ 15.07 — The scenario where the Q1 2026 pace (10.4% pre-IFRS margin) becomes the new normal: Hering does not turn, consumption does not respond and sell-in keeps shrinking. EBITDA of R$ 1,239 mn, FCFF of R$ 649 mn, same 17.3% WACC = R$ 3,111 mn equity. This is what Azzas is worth if it never returns to the margin it has already delivered.
  • DCF — full margin (15.0%): R$ 31.79 — The scenario where Hering stops costing the group ~2 pp of margin (in 2025 the ex-Hering margin would have been 18.4% post-IFRS versus 16.4% reported) and sell-in normalizes. EBITDA of R$ 1,770 mn, FCFF of R$ 1,074 mn = R$ 6,565 mn equity. With the Selic falling toward 11% (Ke 18%), this same scenario is worth R$ 39.04.
  • Balance-sheet floor — tangible book: R$ 13.56 — Independent of both earnings and price. Book equity of R$ 8,005.5 mn less R$ 3,461.8 mn of intangibles (brands + 2024 merger goodwill) less R$ 1,744.5 mn of deferred tax credit (only worth something with future profit) = R$ 2,799 mn of tangible assets ÷ 206.5 mn shares. Below this, a buyer gets inventory, receivables and fixed assets at a discount and the brands for free.
  • FARM Rio optionality (added to the ranges): R$ 8.87 — Multiple arbitrage, not part of the going concern. Estimated FARM EBITDA of R$ 425 mn (our estimate — the company does not disclose EBITDA by brand; the international arm alone posted R$ 1.3 bn of gross revenue over 12 months). Sold at 9x = R$ 3.8 bn, against the 4.7x the conglomerate is worth by our math: unlocks R$ 8.87/share. At 8x it unlocks R$ 6.81; at 10x, R$ 10.93. Only materializes if the deal happens — today it is a hypothesis with no binding proposal.

Timing

Where we stand. The stock broke through its post-merger all-time low (R$ 16.10, set on June 18) and trades at R$ 15.84 — 61% below its 12-month high (R$ 41.10, on July 1, 2025). The most revealing episode of the quarter: on June 19 the company confirmed the Morgan Stanley mandate for FARM and the stock jumped 8.3%; on June 22 it rose another 10.5%, reaching R$ 20.10 the following day on the year's heaviest volume. Five weeks later, that entire premium has been given back — and the stock sits below where it was before the news. Translation: the market tested the value-unlock hypothesis, saw no concrete progress and walked away.

Three clocks are running at once. Macro (Copom on Aug 4-5, Selic at 14.25%, Focus at 14.00% by year-end), operations (Q2 2026 on Aug 12 — the first quarter the company calls "post heavy discounting" at Hering) and corporate (open arbitration and the FARM negotiation). Two of the three strike within the next three weeks. Anyone in a hurry will be served; anyone holding a position should know volatility in that window will be high.

How to act without guessing. There is no prize for front-running Q2 — a 20% upside to our fair value does not pay for the risk of getting the quarter wrong. It makes more sense to let results come out and react: flat revenue with recurring EBITDA margin above 14% validates the base case; another revenue decline with margin below 13% pushes the thesis toward the R$ 12 scenario. And remember what is NOT here: there is no dividend dripping in while you wait.

Management — who runs the company

Management rating: 4.0/10

We cut the score from 4.5 to 4.0 — not because of a scandalous new fact, but because time passed and the proof did not come. Azzas has two owners accustomed to being in sole command: Alexandre Birman (CEO, family holding ~21% of capital) and Roberto Jatahy (Chief Brand Officer, ~10% with his sisters). The power-sharing arrangement designed at the merger collapsed in 2026: Birman reversed a board-approved integration via material fact, Jatahy responded with an injunction and a lawsuit, and the dispute went to CAM-B3 arbitration. June's truce — a new shareholders' agreement and a board elected at April's AGM, chaired by Sylvia Leão Wanderley — still stands, but has not yet been tested by anything hard.

And the hard test has arrived. Deciding whether to sell FARM Rio, at what price, and what to do with the money is precisely the kind of decision that reopens the feud — because FARM came from Jatahy's side, is the only growing vertical (+18.7% in 2025), and is being evaluated under the command of the partner whose vertical is shrinking (Shoes & Bags, -1.2% in 2025). No governance is neutral at that table.

On the positive side, the part of the house that does not depend on the founders is working: CFO Eric Alencar delivered capex -27%, a cash cycle 20 days shorter, debt termed out from 41% to 82.7% long-term and flat fixed expenses in a quarter of falling revenue. That is real competence. Azzas's problem was never operating capability — it is a cap table fighting inside the house, with guidance withdrawn and 8+ senior executives departing in 18 months.

  • Alexandre Café Birman — Chief Executive Officer · co-founder and controlling shareholder. Son of Arezzo's founder, he built Schutz and the international footwear operation. Controls ~21% of capital with his family. A centralizer — his unilateral reversal of the vertical integration in April 2026 triggered the corporate crisis. He leads the company at a moment when the vertical he came from (Shoes & Bags) is shrinking and his partner's (Fashion Women) is growing.
  • Roberto Jatahy — Chief Brand Officer (womenswear and menswear) · co-founder. Creator of Grupo Soma (Animale, FARM Rio, NV). Holds ~10% of capital with his sisters. A consensus-builder, the opposite of Birman's style. He initiated the May 2026 legal and arbitral dispute to preserve his scope of command. The Morgan Stanley review of FARM puts the very brand he built into play.
  • Eric Alexandre Alencar — Chief Financial and Investor Relations Officer. The group's third CFO in two years and, so far, the best news in management: capex -27% in Q1 2026, debt termed out to 82.7% long-term via CDI+1% debentures, a cash cycle 20 days shorter, and R$ 148 mn of operating cash generation in a quarter that consumed R$ 50 mn a year earlier.
  • Sylvia de Souza Leão Wanderley — Chair of the Board of Directors. Chairs a nine-member board — a seat that changed hands three times in ~12 months. Both founding shareholders sit at the table and there are only two formal independents. She will arbitrate the most delicate decision in the company's short history: the fate of FARM Rio.
  • Gustavo Fonseca — Head of the Hering transformation (Basic unit). An 11-year company veteran. He leads the turnaround of the brand that fell 18.5% in Q1 2026 — a decline largely deliberate (channel inventory coverage cut from 8 to 5 months, negative-margin sales eliminated, 47 franchises closed). The company says Q1 was the last quarter of heavy sell-in discounting; Q2 will show whether that is true.

Delivered: the corporate integration completed without operational rupture; gross margin preserved at 54.5%; R$ 667 mn returned to shareholders in 2025; real capital discipline (capex, inventory, cash cycle, debt termed out); FARM Rio international growing 21% in dollars.

Still owed: merger synergies were never quantified to the market and the integration project was reversed mid-feud; the stock fell ~61% in twelve months and broke its all-time low; guidance was withdrawn in March and has not returned; 8+ senior executives left in 18 months; no dividend has been declared in 2026; and revenue fell in a sector that grew. The next test has a date: August 12, Q2 2026 results.

Governance, control and liquidity

On paper the structure is sound: Novo Mercado (100% voting shares, tag along), independent audit and heavyweight institutional investors in the free float (Westwood ~9.5%, BlackRock ~6.1%, Fidelity ~5.0%). In practice, 2026 showed that a shareholders' agreement is worth exactly what the partners want to honor: the Birman × Jatahy dispute ran through a material fact, an injunction, a lawsuit and CAM-B3 arbitration until June's truce. The control bloc holds 34.4% of capital (Birman family ~21.2%, Jatahy family ~10.3%) and the nine-member board seats both founders with only two formal independents — weak counterbalance for a cap table in conflict.

Two market data points complete the picture. First, the company was called four times by the CVM/B3 between May and June 2026 to clarify queries and press reports — a sign that disclosure lagged the facts. Second, 12.8% of capital is sold short (~26.5 mn shares, about 20% of free float) at a low lending fee of 0.29% p.a.: plenty of stock available to borrow and plenty of investors betting on the downside. With R$ 48 mn of average daily liquidity, the stock accommodates large positions — and the headline volatility this saga produces.

  • Control: Shareholders' agreement: 34.4% (Birman ~21.2% + Jatahy ~10.3%)
  • Free float: ~63.5% (Westwood ~9.5% · BlackRock ~6.1% · Fidelity ~5.0%)
  • Shares on loan (short): ~26.5 mn (12.8% of capital · ~20% of free float)
  • Average daily liquidity: ~R$ 48 mn/day
  • Listing: Novo Mercado (B3) · 206.5 mn common shares
  • CVM/B3 inquiries in 2026: 4 clarifications between May and June

Conclusion

This analysis was rebuilt to fix a methodological flaw, not to react to the market. On July 21 we published fair value of R$ 26.00; on July 30, without a single new CVM filing, we cut it to R$ 19.00. The only variable that had changed was the quote. Analysis that follows price informs nothing — it merely describes what already happened. We rebuilt it starting from cash-generating capacity and the country's cost of capital.
What Azzas is worth, without looking at the screen: the company posts R$ 11.8 billion in net revenue and delivered pre-IFRS-16 EBITDA margins of 13.3%, 13.0% and 10.4% in the last three reported quarters. Discounting cash flow at a 17.3% WACC — derived from Brazilian long-term rates, an equity premium and a governance premium, not copied from peers — intrinsic value runs from R$ 15.07 (permanently weak margin) to R$ 31.79 (full margin), centered on R$ 24.36. And there is a floor that depends on no earnings at all: R$ 13.56/share of tangible book, already excluding intangibles and tax credits. That this balance-sheet floor nearly touches the worst corner of the cash flow analysis (R$ 11.96) is the most reassuring convergence in this work.
The warning that changed our reading of the company did not come from the chart, it came from the income statement. In Q1 2026 Azzas reported R$ 63.9 million of recurring profit on pre-tax income of negative R$ 3.7 million — the entire profit was R$ 67.6 million of tax credits. The 2025 pattern repeats on a smaller scale: R$ 770.7 million of recurring profit on roughly R$ 569 million of pre-tax income. The company barely pays tax, between ICMS subsidies and credit utilization, and that inflates reported profit relative to operations. Anyone buying AZZA3 on its "4.6x P/E" is buying a multiple that does not describe the business.
On income, the answer is short: zero dividends declared in 2026, and even in the scenario where profit recovers and the company distributes half of it, the return would be ~0.89% per month — below the 1.11% monthly of Brazil's risk-free Treasury note. There is no income thesis here. What exists is a value thesis with a large, measurable option: FARM Rio sold between 8x and 10x EBITDA unlocks R$ 6.81 to R$ 10.93 per share on top of any range — because the private market pays a multiple for a global brand that a Brazilian conglomerate does not receive.
The ranges, which is what the investor should take away: below R$ 13.50 is a clear opportunity (you pay less than tangible value and get the brands for free); R$ 13.50 to R$ 19.50 is cheap (the price assumes a permanently weak margin AND rates that never fall); R$ 19.50 to R$ 31.50 is fair (you pay for what the company demonstrably does); above R$ 31.50 is expensive (it requires a margin never delivered since the merger). These ranges only move if structural margin, cost of capital, the balance sheet or the corporate structure changes — never because the quote moved.

Analysis produced by Rico aos Poucos with AI assistance, based on public filings (CVM), market data and news. Not investment advice.

Company details (CVM registry)

  • CNPJ (tax ID): 16.590.234/0001-76
  • CVM code: 22349
  • Sector: Textiles & Apparel
  • CVM category: Category A
  • Headquarters: BELO HORIZONTE / MG
  • Investor Relations Officer: Eric Alexandre Alencar
  • Auditor: DELOITTE TOUCHE TOHMATSU AUDITORES INDEPENDENTES LTDA.
  • CVM registration: Jan 31, 2011
  • Status: ACTIVE

Dividends by year

  • 2025: R$ 2.4762 across 2 payment(s)
  • 2024: R$ 1.1159 across 2 payment(s)
  • 2023: R$ 1.9325 across 2 payment(s)
  • 2022: R$ 1.8356 across 3 payment(s)
  • 2021: R$ 0.9270 across 3 payment(s)
  • 2020: R$ 0.5307 across 1 payment(s)
  • 2019: R$ 1.4108 across 5 payment(s)
  • 2018: R$ 1.2848 across 5 payment(s)
  • 2017: R$ 2.0590 across 4 payment(s)
  • 2016: R$ 0.3772 across 2 payment(s)

Recent filings (CVM)

Data content (price, dividends and filings) plus in-house AI-assisted analysis; not investment advice. Sources: B3/Yahoo Finance and CVM (Brazilian SEC).